Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Eli Lilly experienced lower-than-expected sales for its weight loss and diabetes drugs in the third quarter, causing its stock to drop by over 13%. Biogen, on the other hand, exceeded expectations for its Alzheimer's drug Leqembi. Biomarin surpassed sales estimates for its drug Voxzogo, while Sage reported revenue growth for Zurzuvae. Biogen also signed a deal with Neomorph. Additionally, Lilly has modified the dosing of its Alzheimer's drug Kisunlan to lower brain swelling, and Novartis has secured expansion for its CML drug Scemblix. Small funds are investing in early-stage science, and there have been recent job openings in the biotech industry.